
51 - 200 employees
🏥 Healthcare
🍽️ Food & Beverage
🧬 Biotechnology
🔥 Funding within the last year
💰 $30M Post-IPO Secondary - DBV Technologies on 2025-10
Healthcare • Food & Beverage • Biotechnology
DBV Technologies is a global clinical-stage biopharmaceutical company developing epicutaneous immunotherapy to treat food allergies and other immune-mediated diseases. Founded by pediatricians, the company is advancing its proprietary VIASKIN® patch technology through clinical trials—including Phase 3 studies for a peanut allergy patch (DBV712) and earlier-stage programs for milk allergy (DBV135)—with the goal of re-educating the immune system using controlled skin exposure to antigens.
Selected: 🆕 Date Added.
🕒 August 21
Senior Manager executing consumer omnichannel marketing for DBV Technologies’ Viaskin peanut-allergy immunotherapy. Leading agencies, promotional review, digital optimization, campaign analytics, and compliant launch operations.
🏖️ New Jersey – Remote
💵 $155k - $180k / year
🔥 Funding within the last year
💰 $30M Post-IPO Secondary - DBV Technologies on 2025-10
⏰ Full Time
🟠 Senior
⚙️ Operations
👻 Ghost score 0%
🕒 July 21
National Outcomes Director at DBV Technologies focusing on health outcomes and payer engagement for peanut allergy treatment. Collaborating with key stakeholders and driving scientific communications.
🏖️ New Jersey – Remote
💵 $200k - $240k / year
🔥 Funding within the last year
💰 $30M Post-IPO Secondary - DBV Technologies on 2025-10
⏰ Full Time
🔴 Lead
👔 Director
👻 Ghost score 2%
🕒 July 21
National Outcomes Director managing scientific engagement with payers for VIASKIN Peanut. Collaborating on health outcomes research and strategy at DBV Technologies.
🏖️ New Jersey – Remote
💵 $200k - $240k / year
🔥 Funding within the last year
💰 $30M Post-IPO Secondary - DBV Technologies on 2025-10
⏰ Full Time
🔴 Lead
👔 Director
👻 Ghost score 2%